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Abstract (248/250) 
Background and aims: Increased proinsulin relative to insulin levels have been 
associated with subclinical atherosclerosis (measured by carotid intima-media thickness 
(cIMT)) and are predictive of future cardiovascular disease (CVD), independently of 
established risk factors. The mechanisms linking proinsulin to atherosclerosis and CVD 
are unclear. A genome-wide meta-analysis has identified nine loci associated with 
circulating proinsulin levels. Using proinsulin-associated SNPs, we set out to use a 
Mendelian randomisation approach to test the hypothesis that proinsulin plays a causal 
role in subclinical vascular remodelling.   
Methods: We studied the high CVD-risk IMPROVE cohort (n=3,345), which has 
detailed biochemical phenotyping and repeated, state-of-the-art, high-resolution carotid 
ultrasound examinations. Genotyping was performed using Illumina Cardio-Metabo and 
Immuno arrays, which include reported proinsulin-associated loci. Participants with type 
2 diabetes (n=904) were omitted from the analysis. Linear regression was used to 
identify proinsulin-associated genetic variants.  
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Results: We identified a proinsulin locus on chromosome 15 (rs8029765) and 
replicated it in data from 20,003 additional individuals. An 11-SNP score, including the 
previously identified and the chromosome 15 proinsulin-associated loci, was 
significantly and negatively associated with baseline IMTmean and IMTmax (the primary 
cIMT phenotypes) but not with progression measures. However, MR-Eggers refuted any 
significant effect of the proinsulin-associated 11-SNP score, and a non-pleiotropic SNP 
score of three variants (including rs8029765) demonstrated no effect on baseline or 
progression cIMT measures. 
Conclusions: We identified a novel proinsulin-associated locus and demonstrated that 
whilst proinsulin levels are associated with cIMT measures, proinsulin per se is unlikely 
to have a causative effect on cIMT.  
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Introduction 
Hyperinsulinemia, most often a result of systemic insulin resistance, is associated with 
increased risk of cardiovascular disease (CVD) and severity of coronary artery disease 
(CAD) 1. Under normo-glycemic conditions, proinsulin is fully processed to insulin and 
C-peptide before secretion, with very low concentrations of proinsulin being detectable 
in the blood. During hyperinsulinemia, increased demand for insulin production results 
in pancreatic β-cells failing to correctly process proinsulin to mature insulin 2. Thus, 
circulating levels of proinsulin are increased (relative to insulin levels) and this might be 
a link between insulin resistance and CVD. In support of this hypothesis, anti-diabetic 
agents which modulate glucose levels without increasing insulin secretion (for example 
SGLT2-inhibitors) have shown cardiovascular benefits, whilst those which stimulate 
insulin (and potentially proinsulin) secretion, such as sulfonylureas, have shown no CVD 
benefits and in some studies, increased CVD risk 3. Furthermore, subclinical changes in 
the wall of the carotid artery, measured by carotid intima-media thickness (cIMT), have 
been shown to correlate positively with proinsulin levels in healthy individuals 4 and 
increased proinsulin levels have been demonstrated to predict future CVD, 
independently of established risk factors 5-9. However, it remains to be determined 
whether increased proinsulin levels merely reflect CVD risk-related processes, or 
whether proinsulin has a direct adverse functional effect on the vasculature.  
Identification of genetic variants (single nucleotide polymorphisms (SNPs)) convincingly 
associated with circulating proinsulin levels 10 has paved the way for Mendelian 
randomisation (MR) approaches to assess causality of proinsulin on CVD phenotypes. 
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The basis of the MR approaches is that if proinsulin has a causal effect on a 
cardiovascular phenotype, then one would expect that proinsulin-associated genetic 
variants would demonstrate consistent associations with cIMT measures. A gene score 
of proinsulin-associated loci Genetic predisposition to increased proinsulin levels 10 
previously demonstrated no effect on CVD events, however we proposed that increased 
proinsulin levels could be important in earlier stages of CVD development, such as 
those reflected by cIMT. 
The aims of this project were firstly to explore the existence of additional proinsulin-
associated variants using a large panel of candidate loci for metabolic or inflammatory 
processes and secondly to use MR to assess causality of proinsulin on early-stage 
atherosclerosis, represented by cIMT. The IMPROVE cohort is uniquely positioned to 
address the second aim, having extensive genotyping, circulating proinsulin and insulin 
levels and detailed cIMT measurements in 2,441 participants without type 2 diabetes 
(T2D). Accordingly, we set out to test the hypothesis that proinsulin exerts a causal 
detrimental effect on subclinical vascular processes reflected by cIMT. Demonstration 
that proinsulin has a causal role in cIMT would highlight insulin resistance as a target for 
CVD prevention. As insulin sensitisation by dietary, lifestyle and pharmaceutical 
interventions is possible, the role of proinsulin in CVD warrants further investigation.  
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Materials and Methods 
Cohort description: IMPROVE 
The IMPROVE study recruitment and ultrasound protocol have been described in detail 
11, 12. In short, IMPROVE consists of participants without symptoms or history of CVD at 
enrolment, who presented with at least three classical risk factors for CVD (including 
family history of CVD, diabetes or impaired fasting glucose, hypoalphalipoproteinemia, 
hypertension, hypertriglyceridemia, hypercholesterolemia, current smoking 11, 12). 
Between March 2004 and April 2005, 3,711 participants were recruited from seven 
centres in five European countries (Finland, Sweden, the Netherlands, France and 
Italy). Extensive ultrasound examinations of cIMT were carried out at baseline and after 
15 and 30 months, with linear regression of cIMT over time being used to calculate 
cIMT progression variables 11, 12. Primary cIMT phenotypes used in the present study 
were the baseline mean and maximum of the common carotid artery intima-media 
thickness (IMTmean and IMTmax, respectively) 11, 12, as only these baseline measures 
would be available in replication cohorts. Secondary analyses were conducted on 
progression of IMTmean and IMTmax as well as baseline and progression measures of 
additional segments (Online Data Supplement) 11, 12. At baseline, a structured medical 
history and lifestyle questionnaire was completed and blood was sampled. Standard 
clinical and biochemical phenotyping was performed. Participants with T2D (n=904, 
defined as having been diagnosed or treated for diabetes, or fasting glucose ≥7mmol/L) 
were excluded from all analyses. Fasting intact plasma proinsulin was measured with a 
sandwich enzyme-linked immunosorbent assay (DRG Instruments GmbH, Marburg, 
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Germany, Online Data Supplement). Fasting plasma insulin was analysed by 
electrochemiluminescence immunoassay (Meso Scale Discovery, Gaithersburg, MD, 
USA, Online Data Supplement). Cohort characteristics are described in Supplemental 
Table 1. 
Genotyping in IMPROVE  
IMPROVE has been genotyped using both the Illumina CardioMetabo 200k 13 and 
Immunochip 200k 14 bead array platforms. Single nucleotide polymorphisms (SNPs) 
were excluded for low call rate (<95%), low minor allele frequency (<0.01) and for 
deviation from Hardy-Weinberg equilibrium (p<1*10-6). Participants were excluded due 
to low call rate (<95%), aberrant sex assignment or cryptic relatedness (IBD >0.2). 
Multi-dimensional scaling (MDS) components 1-3 were calculated in PLINK 15 to enable 
adjustment for population structure. After quality control 2,441 participants without T2D 
and 254,756 SNPs with minor allele frequency >1% were included in the analysis.  
Identification of proinsulin-associated SNPs in IMPROVE 
To identify proinsulin-associated variants 10, 254,756 SNPs were analysed for influence 
on proinsulin levels. This also enabled assessment of the reported 10 proinsulin-
associated loci. The reported lead 10, the analysed proxy or the strongest SNP for each 
locus are presented in Supplemental Table 2. 
Levels of proinsulin, insulin and glucose were natural log normalised prior to analysis. 
Linear regression, assuming an additive genetic model, was used to analyse the effect 
of single nucleotide polymorphisms (SNPs) on proinsulin levels. To enable comparison 
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of SNP effects with the proinsulin genome-wide association study (GWAS) 10, the same 
three models explored in that paper were tested: insulin model (age, sex, population 
structure and insulin), glucose model (age, sex, population structure, insulin and 
glucose) and body-mass index (BMI) model (age, sex, population structure, insulin and 
BMI). Loci with p<1x10-5 (suggestive evidence of association) in any model were 
selected for replication. Of note, IMPROVE was not part of the prior proinsulin GWAS 10.  
Replication of proinsulin-associated SNPs 
Replication of proinsulin-associated loci was attempted in seven independent cohorts 
(Fenland (http://www.mrc-epid.cam.ac.uk/Research/Studies/Fenland), FHS 16-18, HBCS 
19, PIVUS 20, 21, ULSAM 22, 23, PROCARDIS cases 24 and PROCARDIS controls 24, 
n=18,773-20,003 participants). Replication cohorts are described in the Online Data 
Supplement and cohort characteristics are presented in Supplemental Table 3. The 
same analyses and models as the discovery analysis were applied. To improve power 
and examine consistency of effects, replication results were combined in an inverse 
variance meta-analysis, using GWAMA25.  
Expression quantitative trait locus analysis 
To further characterize the proinsulin-associated locus on chromosome 15 (rs8029765), 
genotype-specific gene expression patterns were assessed. This was conducted in liver 
biopsies from participants undergoing elective surgery for aortic valve and/or ascending 
aortic disease in ASAP 26 (Online Data Supplement) and biopsies from liver or heart and 
peripheral blood mononuclear cells from organ donation or autopsy specimens in the 
GTEx 27 database (Online Data Supplement).  
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In silico analysis of effect on T2D 
Proinsulin-increasing alleles of previously identified SNPs rather surprisingly 
demonstrated a mixture of positive, negative and null effects on T2D risk 10. Thus to 
assess the impact of the novel proinsulin-associated locus on chromosome 15 
(rs8029765) on risk of T2D, an in silico lookup was performed in the DIAGRAM 
consortium data. This study of primarily Europeans included 34,840 T2D cases and 
114,981 controls with GWAS or metabochip data and the results were downloaded from 
the DIAGRAM consortium website (http://diagram-consortium.org/downloads.html). 
Effects of proinsulin on cIMT measures in IMPROVE 
All phenotypes were assessed for normality and natural logarithmic transformation was 
applied where necessary, prior to further statistical analysis. The analysis of proinsulin 
levels for effect on cIMT measures were adjusted in basic (age, sex and population 
structure) and extended models (age, sex, population structure, BMI, systolic blood 
pressure (SBP), high density lipoprotein (HDL), triglycerides (TGs) and current 
smoking)28.  As the mean cIMT measure encompasses the maximum cIMT measure, 
these variables were not considered independent and therefore related, multiple testing 
was not corrected for and p<0.05 was considered significant. Secondary analyses 
explored the consistency of effects of proinsulin on other cIMT segments and on 
analysis of progression measures, where the baseline measure of the same segment 
was also included as a covariate. Because the secondary analyses were exploratory 
only, the size and direction of effects, rather than significance, is the focus of these 
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analyses. Analyses were performed in STATA (STATAcorp LP, College Station, Texas, 
USA). 
Mendelian Randomization (MR) to assess causality of proinsulin on cIMT in 
IMPROVE 
In order to be valid instruments for the MR analyses, the proinsulin-associated loci 
should demonstrate the expected associations with proinsulin levels. Accordingly, the 
effect size and direction were examined for all proinsulin-associated loci 10. Previously 
published results were considered the gold standard (given the much larger sample size 
in the GWAS (n~20,000) compared with this study) and were thus referred to in further 
analyses. Only subjects with complete genotyping for the 11 proinsulin-associated 
SNPs (10 SNPs in 9 reported loci and the chromosome 15 SNP/locus identified here) 
were included in this analysis (N=35 excluded).  
As individual SNPs had only small effects on proinsulin levels, we calculated proinsulin-
associated SNP scores by summing the number of alleles associated with higher 
proinsulin levels. SNP scores were calculated unweighted (sum of number of proinsulin-
increasing alleles) and weighted (sum of the number of alleles multiplied by the effect 
size of the allele reported in the GWAS 10). As there was little difference between the 
variance of proinsulin explained by the unweighted and weighted SNP scores, for 
simplicity the unweighted scores were used for further analysis. The majority of 
proinsulin-associated SNPs have also been associated with other metabolic traits of 
relevance to CVD. This pleiotropy may introduce confounding or explain some of the 
proinsulin associations with cIMT. To determine whether this was the case, a further 
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SNP score was constructed, including only the SNPs which had no reported metabolic 
effects (GWAS catalogue, https://www.ebi.ac.uk/gwas/, Online Data Supplement). 
Analyses were adjusted using the basic model (age, sex and population structure). 
Instrument variable regression, with the proinsulin SNP scores as the instruments, was 
used to assess causality of proinsulin on cIMT variables and was conducted in STATA 
(STATAcorp LP, College Station, Texas, USA). Instrument variable analysis assumes 
that SNPs have no pleiotropic effects. Therefore, Egger’s regression (which can be 
used to assess associations which include pleiotropic SNPs) was also conducted in R 
(Mendelian Randomization package). 
Replication of MR  
Replication of the MR experiment was attempted in 12,113 participants from 5 cohorts 
(2 of which contributed to the SNP-proinsulin replication analysis) with IMTmean and 
IMTmax phenotypes. The replication cohorts are described in the Online Data 
Supplement and characteristics are presented in Supplemental Table 4. The cIMT 
measures were broadly comparable with IMPROVE, with multiple measurements of the 
carotid artery enabling assessment of both the maximum and mean values, both left 
and right carotid arteries being measured (except in ULSAM), and the 1st cm proximal to 
the bifurcation being omitted from common carotid artery measurements (except in 
PIVUS). Meta-analysis of SNP score associations with IMT measures was conducted in 
R using the rma function in the METAFOR package (https://cran.r-
project.org/web/packages/metafor/index.html) 
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Results 
Identification of proinsulin-associated SNPs 
In order to identify proinsulin-associated loci, The combined chip was analysed for 
association with proinsulin levels and adjusted for relevant confounders (consistent with 
the proinsulin GWAS, namely population structure, age, sex, insulin as well as BMI or 
glucose 10).  
Analysis of the combined chip (adjusting for population structure, age, sex, insulin as 
well as BMI or glucose 10) identified Here, a total of 16 SNPs distributed across in 3 loci 
reacheding the suggestive level of significance for association with proinsulin (p<1*10-5) 
(Figure 1 and Supplemental Tables 5 and 6). Consistent with the published proinsulin 
GWAS 10, more proinsulin-associated SNPs were identified using the glucose-adjusted 
model. Most (n=13) of these SNPs were located in the ARAP1 locus. This locus was 
identified previously 10, so this finding was taken to be a positive control and gave us 
confidence in the other loci identified. Conditional analysis for the two known signals 
(rs77756118 and rs11603334) in the ARAP1 locus rendered these SNPs non-significant 
(Figure 2). Two signals were observed: On chromosome 6, rs2323000 and rs6910151 
represent the same signal. On chromosome 15 (rs8029765), the signal is located 29Mb 
from the LARP6 and 20Mb from the VPS13C loci. Conditioning on LARP6 (strongest 
SNP) and VPS13C (reported lead SNP) signals had negligible effects on the 
chromosome 15 signal (Figure 2 and Supplemental Table 7), which thus appeared to be 
a distinct signal. The reason that this SNP was not identified in the previous GWAS 
meta-analysis was most likely its relatively large effect size in IMPROVE (Beta=0.09), 
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compared with that in the GWAS discovery analysis (Beta=0.01)10. A stronger effect 
size in the IMPROVE study compared with the GWAS is plausible: We believe 
proinsulin levels are important in CVD, and the IMPROVE cohort is enriched for CVD 
risk factors. In contrast, the GWAS included a much wider spectrum of CVD burden. 
Hence two proinsulin-associated SNPs, rs2323000 and rs8029765, were taken forward 
to replication. 
Replication of proinsulin-associated SNPs  
Replication results of the two proinsulin-associated SNPs was attempted in from seven 
independent cohorts and results were meta-analysed across all studies (n=18,773-
20,004). The meta-analysis refuted the chromosome 6 locus association with proinsulin 
levels (Table 1). However, nominal significance was observed for the minor allele of 
rs8029765 (chromosome 15) being associated with higher proinsulin levels in most 
models (insulin model: Beta±Se 0.013±0.006, p=0.04 (combined discovery and 
replication 0.020±.006, p=0.001); BMI model: 0.014±0.006, p=0.03 (combined discovery 
and replication 0.020±.006, p=0.002)). Additionally adjusting for glucose did not 
materially alter the effect size (0.012±0.006, p=0.0709 (combined discovery and 
replication 0.020±.006, p=0.003)). The replication meta-analyses indicated that the 
effect sizes in women were not significantly different from those in men (p=0.0659), with 
no evidence of heterogeneity between the strata (I2 =0, sex heterogeneity p=0.80). 
These data provide evidence for a novel proinsulin-associated locus on chromosome 
15, which did not influence risk of T2D (OR 1.00, confidence interval (CI) 0.95-1.06, 
p=0.89, n=51,41129). rs8029765 (and the SNP in high LD, rs4450375, R2>0.8, 
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Supplemental Figure 1) has not previously been reported to be associated with any of 
the metabolic or cardiovascular traits we studied.  
Expression QTL for the chromosome 15 locus 
The relevance of the chromosome 15 locus was assessed by examining nearby genes 
for genotype-specific expression. In the GTEx heart (n=190), liver (n=97) or PBMC 
(n=338) data, generated from relatively healthy individuals, no significant eQTLs were 
identified. However, in the ASAP cohort, which is significantly burdened with 
cardiovascular disease, levels of expression were detectable for eight genes in the 
chromosome 15 locus: MAN2A2, HDDC3, UNC45A, RCCD1, PRC1, VPS33B, SV2B, 
SLCO3A1. In liver samples (n=209), rs8029765 was significantly associated with 
expression of UNC45A (Supplemental Figure 2, p=5.6*10-3) with the proinsulin-
increasing allele demonstrating lower expression of UNC45A. The unc-45 myosin 
chaperone A encoded by the UNC45A gene is a widely expressed chaperone protein 30.  
Effects of Proinsulin on IMTmean and IMTmax. 
As anticipated, proinsulin levels demonstrated correlations with almost all established 
risk variables for CVD in the IMPROVE cohort (Supplemental Table 8). The effect of 
proinsulin levels on measures of cIMT was examined.  For further analysis of IMT 
measures, models were adjusted for relevant confounders 28. No statistically significant 
associations were observed between proinsulin levels and with the primary cIMT 
phenotypes IMTmean and IMTmax. Nominal associations (p<0.05) were observed with the 
IMTmax progression, but not baseline measures, independently of established CVD risk 
factors (Table 2). Secondary analyses indicated that the common carotid (excluding the 
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1st cm proximal to the bifurcation) demonstrated (non-significant) associations between 
higher proinsulin levels and larger cIMT measures (Supplemental Table 9). All other 
segments demonstrated inverse associations.  
Effect of proinsulin-increasing SNP scores on IMTmean and IMTmax 
Reported proinsulin-associated SNPs demonstrated effects sizes generally comparable 
with those previously reported 10 (Supplemental Tables 2 and 10), thus were 
appropriate for use in the MR analysis. A total of 11 proinsulin-associated SNPs were 
included in the SNP score used for the MR analysis (10 previously reported SNPs in 9 
loci and the chromosome 15 SNP, rs8029765). Instrument variable analysis 
demonstrated that the 11-SNP score was significantly and inversely associated with 
baseline IMTmean and IMTmax but not with progression measures (Table 3).  However, 
MR-Eggers (which is more robust when pleiotropy is present 31) refuted a significant 
association between the 11-SNP score and IMTmean (-0.020±0.033 p=0.5721) or IMTmax 
(-0.060±0.054 p=0.2738). As pleiotropic SNPs can bias estimates 31, a further score 
was constructed, using only non-pleiotropic SNPs (SNX7 rs1571500, LARP6 rs7163439 
and UNC45A rs8029765). This SNP score was not associated with baseline or 
progression of cIMT measures (Table 3). Replication of the non-pleiotropic SNP score 
was attempted in 12,113 participants with baseline mean and maximum IMT measures 
comparable with those in IMPROVE. Meta-analysis of the effect of the 3-SNP score on 
baseline IMTmean and IMTmax demonstrated no association (Supplemental Figure 4 and 
Supplemental Table 11). Analyses of secondary IMT phenotypes demonstrated that no 
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single segment differed from the primary phenotypes analysed (Supplemental Table 
12). Proinsulin levels according to SNP score are presented in Supplemental Table 13. 
Mendelian Randomization refutes causality of proinsulin on cIMT 
Proinsulin levels vary over time with and thus a single measurement of levels reflecting 
the exposure of the vasculature to proinsulin at a single point in time. In contrast, the 
proinsulin-increasing SNP score reflects a lifetime of exposure to proinsulin. For 
causality to be demonstrated, the direction of effect of the proinsulin-increasing SNP 
score on cIMT needs to be consistent with the effect of higher levels of proinsulin on 
cIMT. A further requirement is that the SNPs only act on cIMT through proinsulin levels.  
Here, the direction of effect was consistent between proinsulin levels and proinsulin-
increasing SNP scores: higher levels of proinsulin were (non-significantly) associated 
with smaller cIMT measures in IMPROVE and proinsulin-increasing SNP scores were 
associated with smaller cIMT measures. However, this finding does not imply causality, 
because when only the non-pleiotropic SNPs were included in the SNP score, no 
association with cIMT was observed. Taken together, proinsulin per se is unlikely to 
have a causal effect on cIMT.   
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Discussion 
It has previously been reported that circulating levels of proinsulin are predictive of CVD 
5-9. To the best of our knowledge, this is the first study to  examine address the question 
of whether proinsulin has a causal effect on early vascular processes, such as 
increased thickness of the carotid artery wall measured by cIMT. In this study we 
identified a proinsulin-associated locus and used this, and other previously reported 
proinsulin-associated SNPs 10, in a MR experiment, which demonstrated that proinsulin 
is unlikely to be a causal factor in determining cIMT.  
The robust proinsulin-associated loci generally had sizes and directions of effect in 
IMPROVE that were comparable with those previously reported 10, which added support 
to the validity of the proinsulin-associated SNP, and enabled the use of proinsulin SNP 
scores in an MR analysis. The locus (lead SNP rs8029765) demonstrated a genotype-
specific effect on UNC45A expression, with the allele associated with higher levels of 
proinsulin being associated with lower expression of UNC45A. Low levels of UNC45A 
have been shown to inhibit cell proliferation and differentiation whereas high levels are 
associated with a number of cancers 32. The chaperone protein encoded by UNC45A is 
also involved in intra-cellular trafficking, via its association with myosin 32, 33. It is 
possible that genetically low UNC45A levels could influence proinsulin levels, either via 
aberrant trafficking of vesicles (leading to release of incompletely processed proinsulin) 
or as a result of a reduced number of β -cells in the pancreas (leaving the pancreas 
more vulnerable to damaging stress during insulin resistance and hyperinsulinemia). 
Five genetic variants in the UNC45A genomic region have been reported in association 
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with metabolic traits (GWAS catalogue, dated 20161017). However, these are all 
~500kb from the chromosome 15 locus and are at most in low linkage disequilibrium 
with rs8029765 (r2<0.11, Supplemental Figure 3).  In addition, they show no association 
with proinsulin levels in this study (smallest p>0.2411), suggesting that these signals are 
unrelated. The lack of effect of rs8029765 on T2D is consistent with other proinsulin-
associated loci, for example PCSK1, which demonstrated strong effects on proinsulin 
levels but convincingly null effects on T2D10.  
The MR analyses can be used to demonstrate causality if i) proinsulin levels are 
associated with cIMT; ii) SNPs demonstrate robust associations with proinsulin; and iii) 
SNPs influence cIMT only through proinsulin, and not via other mechanisms. Proinsulin 
levels have been shown to influence cIMT in a previous report from a cross-sectional 
study of healthy middle-aged men 4. However, in IMPROVE the association was weak 
and non-significant. Robust associations between SNPs and proinsulin levels have 
been reported 10 and were consistent in IMPROVE. Whilst some association was 
observed between the 11-SNP score and cIMT, adjustment for pleiotropy (using MR-
Eggers) or omission of the pleiotropic SNPs (3-SNP score) rendered the associations 
with cIMT non-significant. These results suggest that associations between proinsulin 
and cIMT are most likely due to confounding and pleiotropic effects of SNPs. Despite 
these findings, CVD prevention strategies which aim to reduce insulin resistance are still 
of value, as insulin resistance promotes other CVD risk factors including obesity and 
leads to T2D. In addition, proinsulin processing to insulin also releases c-peptide, which 
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negatively correlate with HDL levels 34, therefore reducing hyperinsulinemia could 
enable increased HDL levels. 
A limitation of this study is lack of power to detect an association, with much larger 
sample sizes (n>350,000) being required to conclusively address this question. MR 
analyses are frequently weakened by small effect sizes of genetic variants and inability 
to collect large enough sample sizes to enable drawing of definitive conclusions. In the 
absence of sufficient sample sizes with cIMT measures, alternative methodologies 
would be required to confirm these findings. Metabolic phenotypes are particularly 
challenging because of the complexity of interlinking mechanisms.  
A unique strength of this study is the detailed measurements of the cIMT. The 
secondary analyses in the present study demonstrated that a positive association 
between proinsulin and cIMT was limited to only one sengment in the carotid tree, which 
is an interesting and novel observation. However the uniqueness of IMPROVE is also a 
limiting factor in that there are few available cohorts with comparable cIMT measures, 
which precludes replication of the cIMT segments considered in the secondary analysis. 
IMT measures are often rather imprecise, especially when considering progression over 
a relatively short time frame. We recognise this limitation, but note that the standard 
deviations for the studies included in this analysis are not excessive, that there is 
consistency across the studies and we have focused on the baseline measures and 
merely comment upon progression data. The weak association between proinsulin and 
cIMT is a weakness of this study, however there is prior independent evidence for the 
association between proinsulin and cIMT 4. Biomarker measurements reflect a snapshot 
Commentato [RS1]: Don’t want to just say that its crap… or 
were leaving ourselves open to the “then why did you borther 
doing this study?” question! 
If there is a better way of rephrasing this, please let me know! 
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in time, whereas genetic variants reflect the lifetime exposure to biomarker levels. Thus 
by using genetic variants robustly associated with proinsulin levels, MR analyses give a 
more stable lifetime risk assessment. For a genetic discovery analysis, the IMPROVE 
cohort is relatively small. However, the high CVD-risk profile of all subjects renders it a 
relevant cohort for association studies of CVD-associated biomarkers. In addition, all 
participants had at least 3 of 9 established CVD risk factors 12, meaning that the 
repertoire of potential confounders was very varied across the cohort and thereby 
limiting the potential for selection bias. Replication of the chromosome 15 proinsulin-
associated SNP was conducted in a population of similar size to that utilised in the 
proinsulin GWAS 10, thus giving confidence to this finding.  
In conclusion, we have identified a proinsulin-associated locus and used MR to 
demonstrate that proinsulin per se is unlikely to have a causal effect on cIMT, a proxy 
measurement for early atherosclerosis.  
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Figure Legends 
Figure 1: Manhattan plots of the association between SNPs and proinsulin levels in 
participants without T2D, adjusted for the glucose model. SNPs within 250Kb up or 
downstream of SNPs with p<1*10-5 are highlighted in green. 
Figure 2: Regional plots of suggestive loci. (A) Chromosome 11 locus. (B) Chromosome 
11 locus after conditioning on the previously reported ARAP1 loci (rs11603334 and 
rs77756118). (C) Chromosome 15 locus. (D) Chromosome 15 locus adjusted for the 
previously reported, nearby loci (LARP6 rs7163439 and VPS13C rs4502156). (E) 
Chromosome 6 locus. 
 
